Cell Therapy Market, By Therapy Type (Stem Cells, T-cells, Dendritic Cells, NK-cells), By Indication (Oncology, Cardiology, Neurology, Others), By End User (Hospitals, Clinics, Research Institutes), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Apr 2024

Code : CMI5413

Pages :168

Formats :

Excel and PDF

Industry : Biotechnology

Market Concentration and Competitive Landscape

Cell Therapy Market Concentration By Players

Close-monitor your Competitor's Move, Request sample copy

Market Driver – Increasing Number of Regulatory Approvals for Cell Therapy Products

Manufacturers of cell therapy product candidates are engaged in receiving regulatory approvals to enhance their cell therapy process, and this is expected to drive the cell therapy market growth. For instance, in May 2022, the U.S. Food and Drug Administration announced that it had approved Novartis AG’s chimeric antigen receptor (CAR) T-cell therapy, Kymriah, for the treatment of adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

Key Players Insights